American International Group Inc. Sells 3,846 Shares of IDEXX Laboratories, Inc. (IDXX)

American International Group Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,951 shares of the company’s stock after selling 3,846 shares during the period. American International Group Inc.’s holdings in IDEXX Laboratories were worth $4,813,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Strs Ohio increased its holdings in shares of IDEXX Laboratories by 0.7% during the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after buying an additional 41 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of IDEXX Laboratories by 25.3% during the second quarter. Janney Montgomery Scott LLC now owns 3,922 shares of the company’s stock worth $633,000 after buying an additional 792 shares in the last quarter. CIBC Asset Management Inc increased its holdings in shares of IDEXX Laboratories by 3.0% during the second quarter. CIBC Asset Management Inc now owns 10,939 shares of the company’s stock worth $1,766,000 after buying an additional 316 shares in the last quarter. Sei Investments Co. increased its holdings in shares of IDEXX Laboratories by 94.0% during the second quarter. Sei Investments Co. now owns 39,344 shares of the company’s stock worth $6,351,000 after buying an additional 19,067 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of IDEXX Laboratories during the second quarter worth approximately $3,908,000. 86.80% of the stock is owned by institutional investors.

In other IDEXX Laboratories news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $163,678,098.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,000 shares of company stock worth $16,686,200. Insiders own 2.77% of the company’s stock.

Several research firms have recently weighed in on IDXX. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a report on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a research note on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. IDEXX Laboratories has an average rating of “Hold” and a consensus target price of $173.67.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $159.78 on Wednesday. IDEXX Laboratories, Inc. has a 52 week low of $113.71 and a 52 week high of $173.01. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The company has a market cap of $13,518.90, a P/E ratio of 52.19, a PEG ratio of 2.34 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. During the same period in the prior year, the firm earned $0.62 earnings per share. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “American International Group Inc. Sells 3,846 Shares of IDEXX Laboratories, Inc. (IDXX)” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/06/american-international-group-inc-sells-3846-shares-of-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

What are top analysts saying about IDEXX Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit